These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36214412)

  • 1. Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports.
    Xu Y; Song W; Cai Y; Huang R; Wei J; Liu H; Peng X; Zeng K; Li C
    Int J Dermatol; 2023 Mar; 62(3):e144-e146. PubMed ID: 36214412
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
    Li W; Cai S; Man X
    Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
    [No Abstract]   [Full Text] [Related]  

  • 3. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
    Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
    Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
    Saleh M; Reedy M; Torok H; Weaver J
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Dupilumab for the treatment of bullous pemphigoid.
    Wang M; Wang J; Shi B
    Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
    Pop SR; Strock D; Smith RJ
    Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Wang SH; Zuo YG
    Front Immunol; 2021; 12():800609. PubMed ID: 34887875
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous pemphigoid with a prolonged prodrome.
    Nakatani T; Inaoki M; Takehara K
    J Dermatol; 2008 Jul; 35(7):433-6. PubMed ID: 18705831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
    Cao P; Xu W; Zhang L
    Front Immunol; 2022; 13():928621. PubMed ID: 35769474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.
    Halling AS; Zachariae C; Thyssen JP
    Contact Dermatitis; 2020 Jul; 83(1):37-38. PubMed ID: 32087035
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.
    Learned C; Cohen SR; Cunningham K; Alsukait S; Santiago S; Lu J; Rothe M; Nichols A; Rosmarin D
    J Am Acad Dermatol; 2023 Aug; 89(2):378-382. PubMed ID: 37115111
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
    Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
    J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful therapy of pemphigoid gestationis with dupilumab-A new case.
    Alvarez Martinez D; Russo G; Fontao L; Laffitte E
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e752-e753. PubMed ID: 36688319
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
    Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
    Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
    Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
    Hansen I; Gebhardt C; Booken N; Schneider SW
    J Dtsch Dermatol Ges; 2024 Apr; 22(4):587-589. PubMed ID: 38379256
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China.
    Qi W; Rushan X
    Int Immunopharmacol; 2023 May; 118():110050. PubMed ID: 37003187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous pemphigoid-like lesions induced by phenacetin. Report of a case and an immunopathologic study.
    Kashihara M; Danno K; Miyachi Y; Horiguchi Y; Imamura S
    Arch Dermatol; 1984 Sep; 120(9):1196-9. PubMed ID: 6383223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.